New drug combo aims to fight bile duct cancer
NCT ID NCT06591520
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing whether a new immunotherapy drug called AK112, when combined with standard chemotherapy, works better than another immunotherapy (durvalumab) plus the same chemo for people with advanced bile duct cancer. The study includes 682 participants who have not had prior treatment for their advanced cancer. Researchers are measuring how long patients live and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK112 (an experimental immunotherapy drug) combined with gemcitabine and cisplatin chemotherapy
- What this could lead to
- If successful, this could offer a new first-line treatment option for advanced biliary tract cancer, potentially improving survival compared to current standard therapy.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not yet known. The experimental drug may not prove more effective than the existing treatment, and side effects from the combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Zhongshan Hospital, Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers
- New cocktail aims to stop bile duct cancer recurrence
- Blood test may guide cancer care without biopsy